INFLUENZA VIRUS VECTOR FOR VIROTHERAPY

(19)

(11)

EP 3 063 273 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	30.12.2020 Bulletin 2020/53

(45)	Mention of the grant of the patent:
	16.10.2019 Bulletin 2019/42

(21)	Application number: 14809770.2

(22)	Date of filing: 28.10.2014

(51)

International Patent Classification (IPC):

C12N 7/01^(2006.01)
C12N 15/86^(2006.01)

C12N 7/04^(2006.01)
A61K 35/768^(2015.01)

(86)	International application number:
	PCT/EP2014/073120

(87)	International publication number:
	WO 2015/063085 (07.05.2015 Gazette 2015/18)

(54)	INFLUENZA VIRUS VECTOR FOR VIROTHERAPY INFLUENZA-VIRUS-VEKTOR FÜR VIRENTHERAPIE VECTEUR À VIRUS INFLUENZA POUR VIROTHÉRAPIE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

28.10.2013 EP 13190511

(43)	Date of publication of application:
	07.09.2016 Bulletin 2016/36

(73)	Proprietor: Blue Sky Vaccines GmbH
	1060 Vienna (AT)

(72)	Inventor:
	MUSTER, Thomas 1180 Wien (AT)

(74)	Representative: Loidl, Manuela Bettina et al
	REDL Life Science Patent Attorneys Donau-City-Straße 11 1220 Wien 1220 Wien (AT)

(56)

References cited: :

EP-A1- 2 708 552
WO-A2-01/64860

WO-A1-2011/014504

C. L. EFFERSON ET AL: "Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-Oncogene", JOURNAL OF VIROLOGY, vol. 77, no. 13, July 2003 (2003-07), pages 7411-7424, XP055172262, ISSN: 0022-538X, DOI: 10.1128/JVI.77.13.7411-7424.2003
KITTEL CHRISTIAN ET AL: "Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 79, no. 16, August 2005 (2005-08), pages 10672-10677, XP002414818, ISSN: 0022-538X, DOI: 10.1128/JVI.79.16.10672-10677.2005
MUSTER T ET AL: "Interferon resistance promotes oncolysis by influenza virus NSI1-deletion mutants", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 110, no. 1, 20 May 2004 (2004-05-20), pages 15-21, XP008088723, ISSN: 0020-7136, DOI: 10.1002/IJC.20078
M. WOLSCHEK ET AL: "Establishment of a Chimeric, Replication-Deficient Influenza A Virus Vector by Modulation of Splicing Efficiency", JOURNAL OF VIROLOGY, vol. 85, no. 5, 22 December 2010 (2010-12-22), pages 2469-2473, XP055046389, ISSN: 0022-538X, DOI: 10.1128/JVI.01650-10
BERGMANN MICHAEL ET AL: "A genetically engineered influenza A virus with ras-dependent oncolytic properties", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 61, no. 22, 15 November 2001 (2001-11-15), pages 8188-8193, XP002470603, ISSN: 0008-5472 cited in the application
B. FERKO ET AL: "Immunogenicity and Protection Efficacy of Replication-Deficient Influenza A Viruses with Altered NS1 Genes", JOURNAL OF VIROLOGY, vol. 78, no. 23, 12 November 2004 (2004-11-12), pages 13037-13045, XP055090958, ISSN: 0022-538X, DOI: 10.1128/JVI.78.23.13037-13045.2004


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).